Introduction
============

Thyroid cancer (TC) is the most common endocrine malignancy. Incidence of TC has been increasing in the last decade, with approximately three times higher in females than in males [@B1]-[@B3]. Routine inspection is difficult to differentiate benign tumor from malignant thyroid nodules. At present, ultrasonography-guided fine needle aspiration biopsy is the most commonly used diagnostic tool for diagnosing thyroid diseases, especially for small nodules (\< 1.5 cm) and nonpalpable thyroid nodules [@B4]. In addition, diffusion-weighted MR imaging is another vital diagnostic tool for evaluating in vivo tumor characterization and has the potential to differentiate benign from malignant nodules in the thyroid [@B5]-[@B7], but it lacks standard b-values. Hence, it is necessary to screen noninvasive, inexpensive, and sensitive serum biomarkers for differentiating benign thyroid nodules from malignant thyroid nodules.

Serum free fatty acids (FFAs) are important bioactive molecules and are involved in many important metabolic pathways. Emerging evidences have shown that essential fatty acids can modulate the interaction between hormones and their receptors, which can change the expression of receptors on the cells [@B8]. Our previous studies have suggested that significantly decreased unsaturated FFAs (*i.e.*, C~16:1~, C~18:1~, C~18:2~, C~18:3~, C~20:4~, and C~22:6~) are closely correlated with pancreatic cancer [@B9], lung cancer [@B10], and breast cancer [@B11].

In the present study, we have employed chip-based direct-infusion nanoelectrospray-Fourier transform ion cyclotron resonance mass spectrometry (CBDInano ESI-FTICR MS) to simultaneously quantify six FFAs (*i.e.,* C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~) in 664 serum samples from 322 healthy controls, 129 patients with benign thyroid diseases (BTD), and 213 TC patients. Mann-Whitney U test was used to compare differences in serum FFA levels between BTD patients, TC patients, and healthy controls. Our data indicate that a combination of C~16:1~, C~18:2~, C~20:4~, and C~22:6~ has excellent diagnostic accuracy to differentiate BTD patients from TC patients, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.857, a sensitivity of 76.8%, and a specificity of 83.7%.

Materials and Methods
=====================

Chemicals and Reagents
----------------------

Palmitic acid (C~16:0~, purity \> 99%) was from J&K (J&K Scientific Ltd, China). Other fatty acids such as palmitoleic acid (C~16:1~), heptadecenoic acid (C~17:1~), linolenic acid (C~18:3~), linoleic acid (C~18:2~), oleic acid (C~18:1~), arachidonic acid (C~20:4~), heneicosanoic acid (C~21:0~), docosahexaenoic acid (C~22:6~), and ammonium acetate (all purity \>99%, except for C~22:6~ with purity \> 98%) were from Sigma-Aldrich Chemicals. HPLC-grade methanol, ethanol, and acetonitrile were from Fisher Scientific (Pittsburg, PA, USA). The ultrapure water was purified using a Milli-Q system (Millipore, USA).

Participants
------------

In this study, 664 participants were recruited, including 322 healthy controls, 129 BTD patients, and 213 TC patients. Healthy controls were from China-Japan Union Hospital (n=150, Changchun, China) and Heze Municipal Hospital (n=172, Heze, China), respectively. TC patients were from China-Japan Union Hospital (n=88) and from Peking Union Medical College Hospital (n=129, Beijing, China), respectively. All 129 BTD patients were from Peking Union Medical College Hospital. All serum samples used in this study were the remaining sera after clinical laboratory examination, and collected in the morning after overnight fasting of approximately 12 h. All experiments were performed in accordance with relevant guidelines and regulations. The participants gave informed consents, and the study was approved by the Ethics Review Board at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences.

Study design
------------

Characteristics of all participants are shown in **Table [1](#T1){ref-type="table"}**. Serum samples from TC patients were classified into two sets: the training set (n=88) and the validation set (n=125). Healthy controls were age- and sex-matched to TC patients in the training set (n=150) and the validation set (n=172), respectively, and 129 age-and sex-matched BTD patients were put into the validation set to compare differences between healthy controls, TC patients, and BTD patients.

Standard solutions and sample preparation
-----------------------------------------

The calibration standard solutions and serum samples were prepared as our own previous study [@B9]. Briefly, the final concentrations of 83.3 nM heptadecenoic acid (C~17:1~) and 33.3 nM heneicosanoic acid (C~21:0~) as a mixed internal standard (IS) were prepared in ethanol. For calibration standard solutions, a mixture of C~16:1~(342.0 *µ*M), C~18:3~ (81.7 *µ*M), C~18:2~ (569.0 *µ*M), C~18:1~ (836.0 *µ*M), C~20:4~ (183.0 *µ*M), and C~22:6~ (56.2 *µ*M) was dissolved in ethanol, and the diluted 500-fold solution by methanol/acetonitrile/5 mM ammonium acetate in water (42/28/30, v/v/v) was termed as STD1(684.0 nM C~16:1~, 163.5 nM C~18:3~, 1138.0 nM C~18:2~, 1672.0 nM C~18:1~, 366.0 nM C~20:4~, and 112.3 nM C~22:6~). Then the STD1 was further diluted 2-, 10-, 20-, 50- and 80-fold, termed as STD2, STD3, STD4, STD5, and STD6, respectively. These standard solutions were further mixed with 1 *µ*L of the IS solution. The above-mentioned mixtures were employed to construct calibration equations for each of serum FFAs. The STD3 as a quality control sample was also utilized to estimate the experimental reproducibility, and It was analyzed once every 10 test samples during the entire experiment.

After thawing at 4 °C, 50 *µ*L aliquot of each serum sample was mixed with 950 *µ*L of methanol/acetonitrile (3/2, v/v) to precipitate serum proteins followed by vortex-mixing for 30 s and stored at -20 °C overnight. The resulting mixture was centrifuged at 19000 g for 30 min to obtain supernatant, followed by mixing 20 *µ*L aliquot of the supernatant with 1 *µ*L of the IS solution, 500 *µ*L of hexane, and 500 *µ*L of water, and then vortexed for 30 s. After centrifugation at 1500 g for 10 min, the upper hexane layer was transferred into a glass vial and air-dried. The dried sample was re-dissolved by 1 mL of methanol/acetonitrile/5 mM ammonium acetate (42/28/30, v/v/v) in water for mass spectrometric analysis.

Mass Spectrometry
-----------------

All experiments were performed by a 9.4 T Apex-ultra™ hybrid Qh-FTICR MS (Bruker Daltonics, Billerica, MA, USA) equipped with a NanoMate system (Advion BioSciences). The NanoMate system includes a cooling unit set at 4 °C to cool sample solutions and nanoelectrospray source, which includes a 96-well plate, conductive pipette tips, and nanoChip with a 20 × 20 array of nozzle. The sample volume of 0.1 *µ*L was directly infused using a low delivery gas pressure of 0.7 psi, and a voltage of -1.8 kV was applied to the nozzle to generate nanoelectrospray at a flow rate of approximately 100 nL/min.

A mass spectrum was accumulated by 10 full scans over the *m/z*range of 150-400 with the resolution of 200,000 at *m/z*400. A mixture of C~15:0~ (molecular weight, 242.22458 Da), C~17:0~ (270.25588 Da), and C~21:0~ (326.31848 Da) was used to calibrate the instrument. All mass spectra were processed using DataAnalysis 4.0 (Bruker Daltonics). The FFAs were identified based on their observed accurate molecular masses relative to theoretical values with the mass error of ≤ 0.00029 Da and reliable isotope distribution relative to theoretical distribution with relative standard deviation (RSD) of \<2%. The baseline intensity in each spectrum was adopted as their intensities of missing FFAs.

Statistical analysis
--------------------

The Mann-Whitney U test was used to compare differences in serum FFA levels between healthy controls, BTD patients, and TC patients. Significantly changed FFAs (*p*\< 0.05) were submitted to ROC curve analysis to assess their diagnostic accuracy. For the training study, the AUC value, sensitivity, and specificity were obtained based on an optimal cut-off value. For the validation study, the diagnostic models were re-evaluated in term of the cut-off values from the training study. A *p* value of \< 0.05 was considered to be statistically significant. All statistical analyses were performed by the SPSS software (version 16.0, Chicago, IL, USA).

Results and Discussion
======================

Quantitative and qualitative analysis of serum FFAs
---------------------------------------------------

The CBDInanoESI-FTICR MS platform was employed to simultaneously quantify the levels of serum FFAs in 664 participant sera. Calibration equations between the concentration ratios of each fatty acid to IS (C~17:1~ as IS of C~16:1~, C~18:3~, C~18:2~, and C~18:1~ and C~21:0~ as IS of C~20:4~ and C~22:6~) and their corresponding intensity ratios were established, with the correlation coefficients of \>0.993 (**Table [2](#T2){ref-type="table"}**). 68 mass spectra of the quality control sample showed that the RSDs for all analytes were less than \<18% during the entire experiment, indicating that the experimental stability is acceptable for complex biological samples (**Table [2](#T2){ref-type="table"}**), and that high-throughput CBDInanoESI-mass spectrometry is a promising platform for rapid quantification of serum FFAs. Representative mass spectra of serum FFAs from one healthy control, one BTD patient, and one TC patient are shown in **Fig. [1](#F1){ref-type="fig"}**. Six FFA levels were computed on the basis of their respective calibration equations.

Association of change in serum FFA levels with physiological status
-------------------------------------------------------------------

In the training set, comparison of healthy controls and TC patients was performed using Mann-Whitney U test. It was found that significantly decreased FFAs (C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~) in TC patients were observed relative to healthy controls (*p* \< 0.01, **Fig. [2](#F2){ref-type="fig"}**). Change trends in the levels of polyunsaturated fatty acids (PUFAs) (*i.e.*, C~18:2~, C~20:4~, and C~22:6~) are in agreement with the previous data detected in the urine of thyroid cancer patients [@B12]. The ROC curve analysis was performed for each FFA and their combinations, and the results are listed in **Table [3](#T3){ref-type="table"}**. As shown in **Table [3](#T3){ref-type="table"}**, panel a (a combination of C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~) has high diagnostic performance to differentiate TC patients from healthy controls, with an AUC value of 0.847, a sensitivity of 73.9%, and a specificity of 86.0% in the training study. The ROC curve for panel a is shown in **Fig. [3](#F3){ref-type="fig"}a.**

To confirm the association of serum FFA levels with TC, Mann-Whitney U test was further used to an independent validation study including 172 healthy controls, 129 BTD patients, and 125 TC patients, and the results are shown in **Fig. [2](#F2){ref-type="fig"}**. The ROC curve analysis results for each FFA and their combinations are listed in **Table [3](#T3){ref-type="table"}**. In accordance with the training study, significant decreases in the levels of C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~ in TC patients relative to healthy controls were observed, and high diagnostic ability of panel a to differentiate TC patients from healthy controls was observed, with an AUC value of 0.873, a sensitivity of 81.6%, and a specificity of 80.8%. The ROC curve for panel a is shown in **Fig. [3](#F3){ref-type="fig"}b.**

As shown in **Fig. [2](#F2){ref-type="fig"}**, the levels of C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~in BTD patients relative to healthy controls were remarkably decreased. As shown in **Table [3](#T3){ref-type="table"}**, C~20:4~, C~22:6~, PUFAs, and panel a have excellent diagnostic performance to differentiate BTD patients from controls, with the AUC values of \> 0.91, the sensitivities of \> 83%, and the specificities of \> 86%. The ROC curve for panel a is shown in **Fig. [3](#F3){ref-type="fig"}c.** In addition, it is worth noting that significantly decreased C~16:1~, C~18:2~, C~20:4~, and C~22:6~ in BTD patients were detected compared with TC patients (**Fig. [2](#F2){ref-type="fig"}**). Our findings indicate that the lipogenesis of C~16:1~, C~18:2~, C~20:4~, and C~22:6~ may involve in different metabolic pathways between BTD patients and TC patients.

Considering BTD patients and TC patients, the ROC curve analysis indicated that panel b (a combination of C~16:1~, C~18:2~, C~20:4~, and C~22:6~) could exhibit excellent diagnostic ability to differentiate TC patients from BTD patients, with an AUC value of 0.857, a sensitivity of 76.8%, and a specificity of 83.7%. The ROC curve for panel b is shown in **Fig. [3](#F3){ref-type="fig"}d**. Recent years, several immunohistochemical markers, such as cytokeratin-19, galectin-3, HBME-1, fibronectin-1, and intracellular sodium/iodide symporter, or their combinations have been used to differentiate benign thyroid diseases from thyroid cancer, with high specificities of \>90%, and sensitivities from 38% to 98% [@B13]-[@B16]. Other study has indicated that diffusion-weighted MR imaging as a promising non-invasive method to diagnose diseases has high diagnostic ability to differentiate benign from malignant in thyroid lesions, with an AUC value of 0.88, a sensitivity of 76.5%, and a specificity of 100% at b-value of 300 s/mm^2^[@B6], which is similar to our diagnostic ability obtained in this study. In addition, diffusion-weighted MR imaging technology is very complex, easily affected by instrument parameters.

Conclusions
===========

In summary, this study has shown a comprehensive comparison of serum FFAs between healthy controls, BTD patients, and TC patients based on a large serum sample size. Significantly decreased C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~in BTD patients and TC patients were observed compared with healthy controls, and significantly increased C~16:1~, C~18:2~, C~20:4~, and C~22:6~ in TC patients were detected compared with BTD patients. Our findings indicate that lipogenesis of C~16:1~, C~18:2~, C~20:4~, and C~22:6~ may involve in different metabolic pathways between BTD patients and TC patients.
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![Representative negative ion mass spectra of serum FFAs. (a) one healthy control. (b) one patient with benign thyroid diseases, and (c) one patient with thyroid cancer.](jcav06p1276g001){#F1}

![Scatter plots of serum levels of C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~ in healthy controls, patients with benign thyroid disease, and patients with thyroid cancer in the training set and validation set. \*, *p\<*0.05; \*\*, *p*\<0.01; \*\*\*, *p*\<0.001.](jcav06p1276g002){#F2}

![ROC curves. (a) panel a (a combination of C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~) for differentiating the patients with thyroid cancer from healthy controls in the training set. (b) panel a for differentiating the patients with thyroid cancer from healthy controls in the validation set. (c) panel a for differentiating the patients with benign thyroid disease from healthy controls. (d) panel b (a combination of C~16:1~, C~18:2~, C~20:4~, and C~22:6~) for differentiating the patients with thyroid cancer from the patients with benign thyroid disease.](jcav06p1276g003){#F3}

###### 

Demographic and clinical characteristics of all participants in the training set and validation set

                Training Set   Validation Set                           
  ------------- -------------- ---------------- ----------- ----------- -----------
  Male/Female   73/77          26/62            82/90       49/80       22/103
  Age(years)                                                            
  Mean± SD      45.9±9.2       45.6±10.2        47.2±10.3   47.5±13.0   47.9±10.6
  Range         24-73          26-75            22-76       21-75       22-75

SD: standard deviation; TC: thyroid cancer; BTD: benign thyroid disease.

###### 

Calibration equations, correlation coefficient (R^2^), and experimental stability of FAs

  FAs       Linearity (n=3)   RSD (%)                                  
  --------- ----------------- -------------------------------- ------- ------
  C~16:1~   8.5-684.0         Y=0.473(±0.018)X+0.039(±0.011)   0.998   \<15
  C~18:3~   2.0-163.5         Y=1.301(±0.052)X-0.030(±0.010)   0.999   \<18
  C~18:2~   14.2-1138.0       Y=1.614(±0.066)X-0.127(±0.057)   0.998   \<17
  C~18:1~   20.9-1672.0       Y=1.640(±0.029)X+0.464(±0.125)   0.994   \<17
  C~20:4~   4.6-366.0         Y=0.886(±0.039)X-0.063(±0.044)   0.995   \<10
  C~22:6~   1.4-112.3         Y=0.714(±0.035)X-0.029(±0.010)   0.997   \<13

X: Concentration ratios of individual FAs to IS (83.3 nM for C~17:1~ and 33.3 nM for C~21:0~);

Y: Corresponding intensity ratios of FAs to IS; RSD, relative standard deviation.

###### 

The AUC values, cut-off values, sensitivity, and specificity of significantly expressed FFAs between controls and patients

  FFAs      Training set              Validation set                                                                                                                             
  --------- ------------------ ------ ---------------- ------- ------------------- ------ ------ -- ------------------ ------ ------ ------- -- ------------------ ------ ------ -------
  C~16:1~   0.647(.576-.718)   54.7   68.2             36.6    0.589(.521-.658)    58.1   54.4      0.699(.638-.760)   78.5   55.0   30.3       0.611(.543-.680)   60.0   54.3   29.4
  C~18:3~   0.656(.582-.730)   72.0   55.7             17.1    0.803(.750-.857)    85.5   68.8      0.779(.720-.839)   82.6   72.9   16.8                                        
  C~18:2~   0.789(.723-.854)   88.0   63.6             220.8   0.732(.673-.792)    73.3   64.8      0.769(.710-.828)   89.0   61.2   185.7      0.586(.516-.657)   56.0   62.8   189.1
  C~18:1~   0.787(.722-.852)   88.7   59.1             254.6   0.652(.588-.716)    59.3   59.2      0.627(.562-.691)   77.3   46.5   233.0                                       
  C~20:4~   0.781(.718-.844)   78.7   67.0             53.1    0.818(770-.867)     72.1   80.8      0.956(.935-.977)   87.2   91.5   63.4       0.818(.765-.871)   72.8   82.2   43.1
  C~22:6~   0.816(.759-.874)   82.0   67.0             9.1     0.692(.631-.752)    80.2   45.6      0.912(.876-.947)   83.7   86.8   21.9       0.851(.802-.900)   84.0   77.5   15.8
  PUFA      0.845(.790-.900)   68.2   90.0             0.5     0.870(.828-.912)    76.0   84.3      0.960(.941-.979)   83.7   95.3   0.7                                         
  Panel a   0.847(.793-.901)   73.9   86.0             0.5     0.873 (.832-.915)   81.6   80.8      0.968(.951-.985)   87.6   95.3   0.7                                         
  Panel b                                                                                                                                       0.857(.810-.903)   79.8   83.7   0.5

TC: thyroid cancer; BTD: benign thyroid diseases; Sens: Sensitivity; Spec: Specificity; PUFA: polyunsaturated fatty acid; Panel a: C~16:1~, C~18:3~, C~18:2~, C~18:1~, C~20:4~, and C~22:6~; Panel b: C~16:1~, C~18:2~, C~20:4~, and C~22:6~; AUC: area under the receiver operating characteristic curve; CI: confidential interval.
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